Application of antibody-drug conjugates in the treatment of non-small cell lung cancer
10.3760/cma.j.cn371439-20220309-00055
- VernacularTitle:抗体偶联药物在非小细胞肺癌中的应用
- Author:
Jingxian ZHANG
1
;
Dan YI
;
Xiaojiang LI
Author Information
1. 天津中医药大学第一附属医院肿瘤科 国家中医针灸临床医学研究中心，天津 300380
- Keywords:
Antibodies;
Cytotoxins;
Lung neoplasms;
Molecular targeted therapy
- From:
Journal of International Oncology
2022;49(5):296-301
- CountryChina
- Language:Chinese
-
Abstract:
Antibody-drug conjugates (ADCs) have overcome the limitations of traditional chemotherapy and targeted therapy with unique advantage of antibody targeting, and made breakthrough achievements in the treatment of lung cancer. At present, the researches of ADCs in non-small cell lung cancer mainly involve HER2, HER3, TROP2, MET, CEACAM5. Many ADCs have passed rigorous clinical trials, and have shown good safety and efficacy, which provides theoretical basis for individualized treatment of lung cancer.
